Cargando…
Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study
BACKGROUND: Once‐daily topical oxymetazoline cream 1·0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments. OBJECTIVES: To evaluate critically the methodology of clinical trials that require live, static patient assessments by determining...
Autores principales: | Eichenfield, L.F., Del Rosso, J.Q., Tan, J.K.L., Hebert, A.A., Webster, G.F., Harper, J., Baldwin, H.E., Kircik, L.H., Stein‐Gold, L., Kaoukhov, A., Alvandi, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850476/ https://www.ncbi.nlm.nih.gov/pubmed/30500065 http://dx.doi.org/10.1111/bjd.17462 |
Ejemplares similares
-
Oxymetazoline and Energy‐Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open‐Label, Interventional Study
por: Tanghetti, Emil A., et al.
Publicado: (2020) -
A Randomized Controlled Pilot Study: Combined 595‐nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea
por: Sodha, Pooja, et al.
Publicado: (2021) -
Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea
por: Yang, Rongli, et al.
Publicado: (2022) -
Correction to: Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea
por: Yang, Rongli, et al.
Publicado: (2022) -
Evaluation of a simple image‐based tool to quantify facial erythema in rosacea during treatment
por: Logger, Jade G. M., et al.
Publicado: (2020)